Therapy Areas: Autoimmune
AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV
4 February 2026 - US pharmaceutical company AbbVie (NYSE:ABBV) announced on Tuesday that it has submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) ...
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
3 February 2026 - WuXi Biologics (HKG:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Monday that it has entered into a licence and res...
I Peace generates human iPS cells from NKT cells and offers them for research use
2 February 2026 - I Peace Inc, a California-based GMP cell therapy CDMO, announced on Friday that it has generated human induced pluripotent stem (iPS) cells from NKT cells and has started offering th...
Repertoire Immune Medicines teams up with Eli Lilly and Company to develop tolerizing therapies for autoimmune diseases
30 January 2026 - Biotechnology company Repertoire Immune Medicines announced on Thursday that it has entered into a strategic collaboration with pharmaceutical company Eli Lilly and Company (NYSE:LLY...
Formation Bio acquires worldwide rights to FHND5032 from CTFH
30 January 2026 - Formation Bio, an AI-native pharma company, and Chinese pharmaceutical company Jiangsu Chia Tai Feng Hai Pharmaceutical Co Ltd (CTFH) announced on Thursday that Formation Bio has acq...
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
29 January 2026 - WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Wednesday that it has formed a collaboration with ...